Bruno Royer

8.0k total citations
84 papers, 2.5k citations indexed

About

Bruno Royer is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Bruno Royer has authored 84 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Hematology, 32 papers in Genetics and 30 papers in Molecular Biology. Recurrent topics in Bruno Royer's work include Chronic Lymphocytic Leukemia Research (26 papers), Multiple Myeloma Research and Treatments (25 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (22 papers). Bruno Royer is often cited by papers focused on Chronic Lymphocytic Leukemia Research (26 papers), Multiple Myeloma Research and Treatments (25 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (22 papers). Bruno Royer collaborates with scholars based in France, United States and Italy. Bruno Royer's co-authors include Jean‐Paul Fermand, Arnaud Jaccard, Jean‐Claude Brouet, Bertrand Arnulf, Véronique Leblond, Sylvie Chevret, Xavier Mariette, Frank Bridoux, Olivier Hermine and Margaret Macro and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Bruno Royer

74 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bruno Royer France 27 1.3k 1.1k 741 623 414 84 2.5k
Kristina Carlson Sweden 28 987 0.7× 1.3k 1.2× 251 0.3× 988 1.6× 555 1.3× 76 2.5k
Shirley D’Sa United Kingdom 25 469 0.3× 1.4k 1.3× 758 1.0× 628 1.0× 569 1.4× 122 2.4k
Marzia Varettoni Italy 25 721 0.5× 1.3k 1.2× 1.7k 2.2× 790 1.3× 1.2k 2.9× 98 2.8k
Candido E. Rivera United States 19 551 0.4× 858 0.8× 827 1.1× 361 0.6× 392 0.9× 50 1.8k
Norifumi Tsukamoto Japan 25 381 0.3× 826 0.8× 561 0.8× 433 0.7× 706 1.7× 139 2.1k
Jean-Paul Fermand France 11 1.2k 0.9× 735 0.7× 674 0.9× 209 0.3× 210 0.5× 13 1.6k
Rudolf Schlag Germany 16 871 0.6× 973 0.9× 808 1.1× 1.0k 1.6× 669 1.6× 60 2.3k
Murielle Roussel France 21 1.7k 1.3× 1.4k 1.3× 727 1.0× 710 1.1× 80 0.2× 82 2.3k
Micki Klearman United States 17 261 0.2× 455 0.4× 587 0.8× 265 0.4× 200 0.5× 31 2.7k
Chin‐Yang Li United States 29 905 0.7× 1.5k 1.3× 1.8k 2.4× 218 0.3× 424 1.0× 45 3.4k

Countries citing papers authored by Bruno Royer

Since Specialization
Citations

This map shows the geographic impact of Bruno Royer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruno Royer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruno Royer more than expected).

Fields of papers citing papers by Bruno Royer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruno Royer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruno Royer. The network helps show where Bruno Royer may publish in the future.

Co-authorship network of co-authors of Bruno Royer

This figure shows the co-authorship network connecting the top 25 collaborators of Bruno Royer. A scholar is included among the top collaborators of Bruno Royer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruno Royer. Bruno Royer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Moulis, Guillaume, Sylvain Audia, Louis Terriou, et al.. (2025). Efficacy and safety of dapsone in adult primary immune thrombocytopenia. Blood Advances. 9(8). 1976–1983.
2.
Talbot, Alexis, Bruno Royer, Véronique Meignin, et al.. (2025). Teclistamab for heavily pretreated relapsed / refractory POEMS syndrome. Haematologica.
3.
Mahévas, T., Stéphanie Harel, Bruno Royer, et al.. (2024). Plasma cell‐directed therapies induce profound clinical and durable responses in patients with severe or relapsed/refractory scleromyxedema. Journal of the European Academy of Dermatology and Venereology. 39(5). 1011–1016. 2 indexed citations
4.
Carpinteiro, Alexander, Karim Belhadj, Monique C. Minnema, et al.. (2023). Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series. Blood. 143(8). 734–737. 19 indexed citations
5.
Choisy, Caroline, Stéphanie Harel, Bruno Royer, et al.. (2022). CAR‐T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment. SHILAP Revista de lepidopterología. 3(3). 970–974. 21 indexed citations
6.
Talbot, Alexis, Stéphanie Harel, Bruno Royer, et al.. (2021). Thiotepa intrathecal injections for myelomatous central nervous system involvement. British Journal of Haematology. 193(2). e9–e12. 6 indexed citations
7.
Lentzsch, Suzanne, Samuel Pan, Divaya Bhutani, et al.. (2021). Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer Journal. 11(1). 10–10. 70 indexed citations
8.
Nicol, Martin, Virginie Siguret, Giuseppe Vergaro, et al.. (2021). Thromboembolism and Bleeding in Systemic Amyloidosis: A Review. ESC Heart Failure. 9(1). 11–20. 39 indexed citations
9.
Ursu, Rénata, Jérôme LeGoff, Stéphanie Harel, et al.. (2020). 1721P Prolonged positive SARS-CoV-2 RT-PCR in cancer outpatients requires specific reorganization of cancer centres. Annals of Oncology. 31. S1010–S1010. 1 indexed citations
10.
Nicol, Martin, Antoine Deney, Olivier Lairez, et al.. (2020). Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis. European Journal of Heart Failure. 23(2). 231–239. 29 indexed citations
11.
Cohen, Camille, Bruno Royer, Vincent Javaugue, et al.. (2015). Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney International. 88(5). 1135–1143. 79 indexed citations
12.
Paccou, Julien, Éric Desailly, Bérengère Gruson, et al.. (2014). Alterations in bone mineral density and bone turnover markers in newly diagnosed adults with lymphoma receiving chemotherapy: a 1-year prospective pilot study. Annals of Oncology. 25(2). 481–486. 28 indexed citations
13.
Damaj, Gandhi, Florent Malard, Cyrille Hulin, et al.. (2011). Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. Leukemia & lymphoma. 53(4). 632–634. 33 indexed citations
14.
Moreau, Philippe, Arnaud Jaccard, Lotfi Benboubker, et al.. (2010). Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood. 116(23). 4777–4782. 96 indexed citations
15.
Lebon, Delphine, et al.. (2010). Patella plasmacytoma: An unusual localization. American Journal of Hematology. 86(6). 504–504. 2 indexed citations
16.
Etienne, A., Denis Chatelain, Réda Garidi, et al.. (2009). Myelofibrosis-Associated Lymphoproliferative Disease: Retrospective Study of 16 Cases and Literature Review. Advances in Hematology. 2009. 1–5. 7 indexed citations
17.
18.
Royer, Bruno, Bertrand Arnulf, Frank Martinez, et al.. (2004). High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney International. 65(2). 642–648. 75 indexed citations
19.
Fermand, Jean‐Paul & Bruno Royer. (2001). Thalidomide et myélome : le renouveau d'un médicament décrié. 7(7). 552–555. 1 indexed citations
20.
Brouet, Jean‐Claude, et al.. (2000). Study of the B cell memory compartment in common variable immunodeficiency. European Journal of Immunology. 30(9). 2516–2520. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kristina Carlson Breakdown of academic impact, for papers by Shirley D’Sa Breakdown of academic impact, for papers by Marzia Varettoni Breakdown of academic impact, for papers by Candido E. Rivera Breakdown of academic impact, for papers by Norifumi Tsukamoto Breakdown of academic impact, for papers by Jean-Paul Fermand Breakdown of academic impact, for papers by Rudolf Schlag Breakdown of academic impact, for papers by Murielle Roussel Breakdown of academic impact, for papers by Micki Klearman Breakdown of academic impact, for papers by Chin‐Yang Li
Rankless by CCL
2026